Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2015, Article ID 627631, 9 pages
http://dx.doi.org/10.1155/2015/627631
Research Article

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

1Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
2Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
3Optum, 950 Winter Street, Suite 2800, Waltham, MA 02451, USA
4Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA

Received 3 September 2015; Accepted 3 November 2015

Academic Editor: Salvatore Minisola

Copyright © 2015 Stuart Silverman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Kanis, O. Johnell, A. Oden, A. Dawson, C. De Laet, and B. Jonsson, “Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds,” Osteoporosis International, vol. 12, no. 12, pp. 989–995, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Ström, F. Borgström, J. A. Kanis et al., “Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA),” Archives of Osteoporosis, vol. 6, no. 1-2, pp. 59–155, 2011. View at Publisher · View at Google Scholar
  3. E. Orwoll, M. Ettinger, S. Weiss et al., “Alendronate for the treatment of osteoporosis in men,” The New England Journal of Medicine, vol. 343, no. 9, pp. 604–610, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Ringe, P. Farahmand, H. Faber, and A. Dorst, “Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study,” Rheumatology International, vol. 29, no. 3, pp. 311–315, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Burge, B. Dawson-Hughes, D. H. Solomon, J. B. Wong, A. King, and A. Tosteson, “Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025,” Journal of Bone and Mineral Research, vol. 22, no. 3, pp. 465–475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. Prolia Prescribing Information, http://pi.amgen.com/united_states/prolia/prolia_pi.pdf.
  7. B. Jönsson, O. Ström, J. A. Eisman et al., “Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis,” Osteoporosis International, vol. 22, no. 3, pp. 967–982, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Parthan, M. M. Deflin, N. Yurgin, J. Huang, and D. C. Taylor, “Cost-effectiveness of denosumab versus oral bisphosphonates in the United States for Post-Menopausal Osteoporosis (PMO),” Value in Health, vol. 15, no. 4, article A38, 2012. View at Publisher · View at Google Scholar
  9. S. Boonen, J. D. Adachi, Z. Man et al., “Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 6, pp. 1727–1736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. McClung, S. Boonen, O. Törring et al., “Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis,” Journal of Bone and Mineral Research, vol. 27, no. 1, pp. 211–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. National Institute for Health and Clinical Excellence (UK), Systematic Reviews of Clinical Effectiveness Prepared for the Guideline “Osteoporosis: Assessment of Fracture Risk and the Prevention of Osteoporotic Fractures in Individuals at High Risk”, National Collaborating Centre for Nursing and Supportive Care, 2008, http://www.nice.org.uk/guidance?action=download&o=42362.
  12. C. A. Inderjeeth, A. C. H. Foo, M. M. Y. Lai, and P. Glendenning, “Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence,” Bone, vol. 44, no. 5, pp. 744–751, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Boonen, D. M. Black, C. S. Colón-Emeric et al., “Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older,” Journal of the American Geriatrics Society, vol. 58, no. 2, pp. 292–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. R. McClung, P. Geusens, P. D. Miller et al., “Effect of risedronate on the risk of hip fracture in elderly women,” The New England Journal of Medicine, vol. 344, no. 5, pp. 333–340, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Parthan, M. Kruse, I. Agodoa, S. Silverman, and E. Orwoll, “Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective,” Bone, vol. 59, pp. 105–113, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Orwoll, C. S. Teglbjærg, B. L. Langdahl et al., “A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 9, pp. 3161–3169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. ADAMO trial data. Data on file-Amgen, Internal data.
  18. S. R. Cummings, J. S. Martin, M. R. McClung et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 361, no. 8, pp. 756–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. E. S. Orwoll, N. C. Binkley, E. M. Lewiecki, U. Gruntmanis, M. A. Fries, and G. Dasic, “Efficacy and safety of monthly ibandronate in men with low bone density,” Bone, vol. 46, no. 4, pp. 970–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-M. Kaufman, M. Audran, G. Bianchi et al., “Efficacy and safety of strontium ranelate in the treatment of male osteoporosis,” Osteoporosis International, vol. 23, supplement 2, pp. S85–386, 2012. View at Google Scholar
  21. Actonel (risedronate sodium) Prescribing Information, http://pi.actavis.com/data_stream.asp?product_group=1874&p=pi&language=E.
  22. T. Majima, A. Shimatsu, Y. Komatsu et al., “Efficacy of risedronate in Japanese male patients with primary osteoporosis,” Internal Medicine, vol. 47, no. 8, pp. 717–723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Boonen, J.-Y. Reginster, J.-M. Kaufman et al., “Fracture risk and zoledronic acid therapy in men with osteoporosis,” The New England Journal of Medicine, vol. 367, no. 18, pp. 1714–1723, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. EMEA and Committee for Medicinal Products for Human Use, Guideline on the Evaluation of Medicinal Products in the Treatmentof Primary Osteoporosis, EMEA, 2006.
  25. E. Landfeldt, O. Ström, S. Robbins, and F. Borgström, “Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA),” Osteoporosis International, vol. 23, no. 2, pp. 433–443, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Weycker, D. Macarios, J. Edelsberg, and G. Oster, “Compliance with drug therapy for postmenopausal osteoporosis,” Osteoporosis International, vol. 17, no. 11, pp. 1645–1652, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Freemantle, S. Satram-Hoang, E.-T. Tang et al., “Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women,” Osteoporosis International, vol. 23, no. 1, pp. 317–326, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Jönsson, C. Christiansen, O. Johnell, J. Hedbrandt, and G. Karlsson, “Cost-effectiveness of fracture prevention in established osteoporosis,” Scandinavian Journal of Rheumatology, vol. 25, no. 103, pp. 30–38, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. NICE, “Osteoporosis—secondary prevention including strontium ranelate: appraisal consultation document,” 2008, http://www.nice.org.uk.
  30. O. Johnell, B. Jönsson, L. Jönsson, and D. Black, “Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures,” PharmacoEconomics, vol. 21, no. 5, pp. 305–314, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. D. M. Black, A. V. Schwartz, K. E. Ensrud et al., “Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial long-term extension (FLEX): a randomized trial,” The Journal of the American Medical Association, vol. 296, no. 24, pp. 2927–2938, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Z. Bagger, L. B. Tankó, P. Alexandersen, P. Ravn, and C. Christiansen, “Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal,” Bone, vol. 33, no. 3, pp. 301–307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. L. J. Melton III, C. S. Crowson, and W. M. O'Fallon, “Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time,” Osteoporosis International, vol. 9, no. 1, pp. 29–37, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Hasserius, M. K. Karlsson, B. E. Nilsson, I. Redlund-Johnell, and O. Johnell, “Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study,” Osteoporosis International, vol. 14, no. 1, pp. 61–68, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Cooper, E. J. Atkinson, W. M. O'Fallon, and L. J. Melton III, “Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989,” Journal of Bone and Mineral Research, vol. 7, no. 2, pp. 221–227, 1992. View at Google Scholar · View at Scopus
  36. T. Peasgood, K. Herrmann, J. A. Kanis, and J. E. Brazier, “An updated systematic review of health state utility values for osteoporosis related conditions,” Osteoporosis International, vol. 20, no. 6, pp. 853–868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. A. Kanis, O. Johnell, A. Oden et al., “The risk and burden of vertebral fractures in Sweden,” Osteoporosis International, vol. 15, no. 1, pp. 20–26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Borgström, B. Jönsson, O. Ström, and J. A. Kanis, “An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials,” Osteoporosis International, vol. 17, no. 12, pp. 1781–1793, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. K. Brenneman, N. Yurgin, and Y. Fan, “Cost and management of males with closed fractures,” Osteoporosis International, vol. 24, no. 3, pp. 825–833, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. A. N. A. Tosteson, L. J. Melton III, B. Dawson-Hughes et al., “Cost-effective osteoporosis treatment thresholds: the United States perspective,” Osteoporosis International, vol. 19, no. 4, pp. 437–447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. Physician's Fee and Coding Guide 2013, MAG Mutual Healthcare Solutions, 2012.
  42. WAC 2013, http://www.encoderpro.com/.
  43. O. Johnell, J. A. Kanis, A. Odén et al., “Mortality after osteoporotic fractures,” Osteoporosis International, vol. 15, no. 1, pp. 38–42, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. Swedish Life Tables 2010, http://www.mortality.org/.
  45. J. Hanmer, W. F. Lawrence, J. P. Anderson, R. M. Kaplan, and D. G. Fryback, “Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores,” Medical Decision Making, vol. 26, no. 4, pp. 391–400, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. J. E. Siegel, G. W. Torrance, L. B. Russell, B. R. Luce, M. C. Weinstein, and M. R. Gold, “Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine,” PharmacoEconomics, vol. 11, no. 2, pp. 159–168, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. K. F. Huybrechts, K. J. Ishak, and J. J. Caro, “Assessment of compliance with osteoporosis treatment and its consequences in a managed care population,” Bone, vol. 38, no. 6, pp. 922–928, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. D. H. Solomon, J. Avorn, J. N. Katz et al., “Compliance with osteoporosis medications,” Archives of Internal Medicine, vol. 165, no. 20, pp. 2414–2419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. J. A. Kanis, J. Adams, F. Borgström et al., “The cost-effectiveness of alendronate in the management of osteoporosis,” Bone, vol. 42, no. 1, pp. 4–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Liu, K. Michaud, S. Nayak, D. B. Karpf, D. K. Owens, and A. M. Garber, “The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis,” Archives of Internal Medicine, vol. 166, no. 11, pp. 1209–1217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. J. A. Kanis, J.-Y. Reginster, J.-M. Kaufman et al., “A reappraisal of generic bisphosphonates in osteoporosis,” Osteoporosis International, vol. 23, no. 1, pp. 213–221, 2012. View at Publisher · View at Google Scholar · View at Scopus